These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 9544684

  • 41. Evaluation of 99mTc-MAMA-chrysamine G as an in vivo probe for amyloidosis.
    Dezutter NA, Landman WJ, Jager PL, de Groot TJ, Dupont PJ, Tooten PC, Zekarias B, Gruys E, Verbruggen AM.
    Amyloid; 2001 Sep; 8(3):202-14. PubMed ID: 11676297
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Diagnostic tools for amyloidosis.
    Hachulla E, Grateau G.
    Joint Bone Spine; 2002 Dec; 69(6):538-45. PubMed ID: 12537260
    [Abstract] [Full Text] [Related]

  • 44. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
    Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN.
    Nature; 2002 May 16; 417(6886):254-9. PubMed ID: 12015594
    [Abstract] [Full Text] [Related]

  • 45. [AL- and AA-amyloidosis (the status of the problem)].
    Kochubeĭ LN, Vinogradova OM, Serov VV, Vasil'eva NA, Tomas NIu.
    Klin Med (Mosk); 1988 Aug 16; 66(8):7-16. PubMed ID: 3057283
    [No Abstract] [Full Text] [Related]

  • 46. Amyloid load in fat tissue reflects disease severity and predicts survival in amyloidosis.
    van Gameren II, Hazenberg BP, Bijzet J, Haagsma EB, Vellenga E, Posthumus MD, Jager PL, van Rijswijk MH.
    Arthritis Care Res (Hoboken); 2010 Mar 16; 62(3):296-301. PubMed ID: 20391474
    [Abstract] [Full Text] [Related]

  • 47. AA amyloidosis complicating the hereditary periodic fever syndromes.
    Lane T, Loeffler JM, Rowczenio DM, Gilbertson JA, Bybee A, Russell TL, Gillmore JD, Wechalekar AD, Hawkins PN, Lachmann HJ.
    Arthritis Rheum; 2013 Apr 16; 65(4):1116-21. PubMed ID: 23280696
    [Abstract] [Full Text] [Related]

  • 48. Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis.
    Hawkins PN, Tennent GA, Woo P, Pepys MB.
    Clin Exp Immunol; 1991 May 16; 84(2):308-16. PubMed ID: 1673879
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Serum amyloid P component enhances induction of murine amyloidosis.
    Togashi S, Lim SK, Kawano H, Ito S, Ishihara T, Okada Y, Nakano S, Kinoshita T, Horie K, Episkopou V, Gottesman ME, Costantini F, Shimada K, Maeda S.
    Lab Invest; 1997 Nov 16; 77(5):525-31. PubMed ID: 9389795
    [Abstract] [Full Text] [Related]

  • 51. The pattern recognition reagents RAGE VC1 and peptide p5 share common binding sites and exhibit specific reactivity with AA amyloid in mice.
    Kennel SJ, Williams A, Stuckey A, Richey T, Wooliver C, Chazin W, Stern DA, Martin EB, Wall JS.
    Amyloid; 2016 Nov 16; 23(1):8-16. PubMed ID: 26701064
    [Abstract] [Full Text] [Related]

  • 52. Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature.
    Lane T, Gillmore JD, Wechalekar AD, Hawkins PN, Lachmann HJ.
    Clin Exp Rheumatol; 2015 Nov 16; 33(6 Suppl 94):S46-53. PubMed ID: 26120866
    [Abstract] [Full Text] [Related]

  • 53. Classification of amyloidosis: immunohistochemistry versus the potassium permanganate method in differentiating AA from AL amyloidosis.
    Janssen S, Elema JD, van Rijswijk MH, Limburg PC, Meijer S, Mandema E.
    Appl Pathol; 1985 Nov 16; 3(1-2):29-38. PubMed ID: 3915945
    [Abstract] [Full Text] [Related]

  • 54. Pathogenesis, diagnosis and treatment of systemic amyloidosis.
    Pepys MB.
    Philos Trans R Soc Lond B Biol Sci; 2001 Feb 28; 356(1406):203-10; discussion 210-1. PubMed ID: 11260801
    [Abstract] [Full Text] [Related]

  • 55. Transmission of systemic AA amyloidosis in animals.
    Murakami T, Ishiguro N, Higuchi K.
    Vet Pathol; 2014 Mar 28; 51(2):363-71. PubMed ID: 24280941
    [Abstract] [Full Text] [Related]

  • 56. Demonstration of amyloid A (AA) protein and amyloid P component (AP) in deposits of systemic amyloidosis associated with renal adenocarcinoma.
    Hind CR, Tennent GA, Evans DJ, Pepys MB.
    J Pathol; 1983 Feb 28; 139(2):159-66. PubMed ID: 6338184
    [Abstract] [Full Text] [Related]

  • 57. In vitro affinity of 99Tcm-labelled N2S2 conjugates of chrysamine G for amyloid deposits of systemic amyloidosis.
    Dezutter NA, Sciot RM, de Groot TJ, Bormans GM, Verbruggen AM.
    Nucl Med Commun; 2001 May 28; 22(5):553-8. PubMed ID: 11388578
    [Abstract] [Full Text] [Related]

  • 58. Clinical, radiological and serum amyloid P component scintigraphic features of beta2-microglobulin amyloidosis associated with continuous ambulatory peritoneal dialysis.
    Tan SY, Baillod R, Brown E, Farrington K, Soper C, Percy M, Clutterbuck E, Madhoo S, Pepys MB, Hawkins PN.
    Nephrol Dial Transplant; 1999 Jun 28; 14(6):1467-71. PubMed ID: 10383009
    [Abstract] [Full Text] [Related]

  • 59. [Multisystemic amyloidosis. Clinical study of 39 patients in Lebanon].
    Saba M, Tohmé A, Abadjian G, Haddad F, Ghayad E.
    Presse Med; 2005 May 14; 34(9):640-6. PubMed ID: 15988337
    [Abstract] [Full Text] [Related]

  • 60. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.
    Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, Hawkins PN.
    Br J Haematol; 2003 Jul 14; 122(1):78-84. PubMed ID: 12823348
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.